Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 4/2014

01.12.2014 | short review

Lung cancer: ASCO 2014 update

verfasst von: Ferdinand Ploner

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

At the American Society of Clinical Oncology (ASCO) meeting 2014, the most striking abstracts on lung cancer treatment addressed—as expected—aspects of targeted therapy. The most probable practice changing data came from the presentation of the PROFILE 1014 trial dealing with anaplastic lymphoma kinase-positive non-small-cell lung carcinoma patients treated with crizotinib or chemotherapy in the first-line setting, which confirmed a comparable degree of benefit from crizotinib treatment as reported in second-line treatment. After 10 years of epidermal growth factor receptor (EGFR)-directed therapy, there were for the first time reports on phase I data on new agents showing efficacy in tyrosine-kinase inhibitor pre-treated patients with secondary resistance (i.e. T790M mutation). Monoclonal antibodies directed against EGFR and vascular endothelial growth factor receptor given in addition to conventional chemotherapy (SQUIRE and REVEL, respectively) resulted in significant but less impressive results. Notable improvements in overall survival in these two studies were not restricted to patients with adenocarcinoma but proved beneficial in patients with squamous cell carcinoma as well. Unfortunately, as in the aftermath of many past ASCO meetings, there will be no significant changes concerning systemic treatment of small cell lung cancer in the near future.
Literatur
1.
Zurück zum Zitat Vansteenkiste J, De Ruysscher D, Eberhardt WE, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl. 6):vi89–98. Vansteenkiste J, De Ruysscher D, Eberhardt WE, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl. 6):vi89–98.
2.
Zurück zum Zitat Goss GD, O’Callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 Study. J Clin Oncol. 2013;31:3320–6.PubMedCentralPubMedCrossRef Goss GD, O’Callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 Study. J Clin Oncol. 2013;31:3320–6.PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Kelly K, Altorki NK, Eberhardt WE, et al. A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results. J Clin Oncol. 2014;32:5s (suppl; abstr 7501).CrossRef Kelly K, Altorki NK, Eberhardt WE, et al. A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results. J Clin Oncol. 2014;32:5s (suppl; abstr 7501).CrossRef
4.
Zurück zum Zitat Shepherd FA, Altorki NK, Eberhardt WE, et al. Adjuvant erlotinib vs placebo in non-small cell lung cancer (NSCLC) patients with tumors carrying EGFR sensitizing mutations from the RADIANT Trial. J Clin Oncol. 2014;32:5s (suppl; abstr 7513).CrossRef Shepherd FA, Altorki NK, Eberhardt WE, et al. Adjuvant erlotinib vs placebo in non-small cell lung cancer (NSCLC) patients with tumors carrying EGFR sensitizing mutations from the RADIANT Trial. J Clin Oncol. 2014;32:5s (suppl; abstr 7513).CrossRef
5.
Zurück zum Zitat Pennell NA, Neal JW, Chaft JE, et al. SELECT: a multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. J Clin Oncol. 2014;32:5s (suppl; abstr 7514).CrossRef Pennell NA, Neal JW, Chaft JE, et al. SELECT: a multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. J Clin Oncol. 2014;32:5s (suppl; abstr 7514).CrossRef
6.
Zurück zum Zitat Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:iii27–39 (pii: mdu199). Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:iii27–39 (pii: mdu199).
7.
Zurück zum Zitat Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet. 2009;373:1525–31.PubMedCrossRef Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet. 2009;373:1525–31.PubMedCrossRef
8.
Zurück zum Zitat Thatcher N, Hirsch FR, Szczesna A, et al. A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). J Clin Oncol. 2014;32:5s (suppl; abstr 8008).CrossRef Thatcher N, Hirsch FR, Szczesna A, et al. A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). J Clin Oncol. 2014;32:5s (suppl; abstr 8008).CrossRef
9.
Zurück zum Zitat Perol M, Ciuleanu TE, Arrieta O, et al. REVEL: a randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy. J Clin Oncol. 2014;32:5s (suppl; abstr LBA8006).CrossRef Perol M, Ciuleanu TE, Arrieta O, et al. REVEL: a randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy. J Clin Oncol. 2014;32:5s (suppl; abstr LBA8006).CrossRef
10.
Zurück zum Zitat Ellis LM, Bernstein DS, Voest EE, et al. American Society of Clinical Oncology Perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014;32:1277–80.PubMedCrossRef Ellis LM, Bernstein DS, Voest EE, et al. American Society of Clinical Oncology Perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014;32:1277–80.PubMedCrossRef
11.
Zurück zum Zitat Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized Phase II Trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2013;31:4105–14.PubMedCrossRef Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized Phase II Trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2013;31:4105–14.PubMedCrossRef
12.
Zurück zum Zitat Spigel DR, Edelman MJ, O’Byrne K, et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971 g) global trial. J Clin Oncol. 2014;32:5s (suppl; abstr 8000).CrossRef Spigel DR, Edelman MJ, O’Byrne K, et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971 g) global trial. J Clin Oncol. 2014;32:5s (suppl; abstr 8000).CrossRef
13.
Zurück zum Zitat Kato T, Seto T, Nishio M, et al. Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation-positive nonsquamous non-small cell lung cancer (NSCLC): an open-label randomized trial. J Clin Oncol. 2014;32:5s (suppl; abstr 8005).CrossRef Kato T, Seto T, Nishio M, et al. Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation-positive nonsquamous non-small cell lung cancer (NSCLC): an open-label randomized trial. J Clin Oncol. 2014;32:5s (suppl; abstr 8005).CrossRef
14.
Zurück zum Zitat Yang JCH, Sequist LV, Schuler MH, et al. Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT). J Clin Oncol. 2014;32:5s (suppl; abstr 8004).CrossRef Yang JCH, Sequist LV, Schuler MH, et al. Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT). J Clin Oncol. 2014;32:5s (suppl; abstr 8004).CrossRef
15.
Zurück zum Zitat Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol. 2013;31:3987–96.PubMedCentralPubMedCrossRef Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol. 2013;31:3987–96.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Janne PA, Ramalingam SS, Yang JCH, et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32:5s (suppl; abstr 8009).CrossRef Janne PA, Ramalingam SS, Yang JCH, et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32:5s (suppl; abstr 8009).CrossRef
17.
Zurück zum Zitat Sequist LV, Soria JC, Gadgeel SM, et al. First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). J Clin Oncol. 2014;32:5s (suppl; abstr 8010).CrossRef Sequist LV, Soria JC, Gadgeel SM, et al. First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). J Clin Oncol. 2014;32:5s (suppl; abstr 8010).CrossRef
18.
Zurück zum Zitat Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94.PubMedCrossRef Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94.PubMedCrossRef
19.
Zurück zum Zitat Mok T, Kim DW, Wu YL, et al. First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). J Clin Oncol. 2014;32:5s (suppl; abstr 8002).CrossRef Mok T, Kim DW, Wu YL, et al. First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). J Clin Oncol. 2014;32:5s (suppl; abstr 8002).CrossRef
20.
Zurück zum Zitat Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664–72.PubMedCrossRef Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664–72.PubMedCrossRef
21.
Zurück zum Zitat Seto T, Takahashi T, Yamanaka T, et al. Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): results of a Japanese randomized phase III trial. J Clin Oncol. 2014;32:5s (suppl; abstr 7503).CrossRef Seto T, Takahashi T, Yamanaka T, et al. Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): results of a Japanese randomized phase III trial. J Clin Oncol. 2014;32:5s (suppl; abstr 7503).CrossRef
22.
Zurück zum Zitat Slotman BJ, Faivre-Finn C, van Tinteren H, et al. Randomized trial on thoracic radiotherapy (TRT) in extensive-stage small cell lung cancer. J Clin Oncol. 2014;32:5s (suppl; abstr 7502).CrossRef Slotman BJ, Faivre-Finn C, van Tinteren H, et al. Randomized trial on thoracic radiotherapy (TRT) in extensive-stage small cell lung cancer. J Clin Oncol. 2014;32:5s (suppl; abstr 7502).CrossRef
23.
Zurück zum Zitat Slotman BJ, van Tinteren H, O Praag J, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2014 doi:10.1016/S0140-6736(14)61085-0. Slotman BJ, van Tinteren H, O Praag J, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2014 doi:10.1016/S0140-6736(14)61085-0.
Metadaten
Titel
Lung cancer: ASCO 2014 update
verfasst von
Ferdinand Ploner
Publikationsdatum
01.12.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0180-6

Weitere Artikel der Ausgabe 4/2014

memo - Magazine of European Medical Oncology 4/2014 Zur Ausgabe